Corbus Pharmaceuticals
Highly Engaged Employees
Highly Engaged EmployeesBusiness Services · Massachusetts, United States · 11-50 Employees
View Company Info for Free
Overview
Headquarters
500 River Ridge Dr, Norwood, Massachuset...Phone Number
(617) 963-0100Website
www.corbuspharma.comRevenue
<$5 MillionStock Symbol
CRBPIndustry
ZI Rank: 1
Signal Type
Mar
Apr
May
Jun
Jul
Aug
ZI Rank
2
1
1
2
1
1
About Corbus Pharmaceuticals
Corbus Pharmaceuticals Holdings, Inc., a biopharmaceutical company, develops products to defeat serious illness. It develops CRB-701, an antibody drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload of monomethyl auristatin E (MMAE), which is in Phase I clinical trial; CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGF expressed on cancer cells for the treatment of solid tumors; CRB-913, a peripherally restricted cannabinoid type-1 (CB1) receptor inverse agonist for the treatment of obesity. It has a licensing agreement with Jenrin Discovery, LLC to develop and commercialize the licensed products, including the Jenrin library of approximately 600 compounds, and multiple issued and pending patent filings. The company was incorporated in 2009 and is based in Norwood, Massachusetts.Explore more
Corbus Pharmaceuticals Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Corbus Pharmaceuticals your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Funding: Get notified immidiatlly once Corbus Pharmaceuticals has new funding data
Earning: See what the market has to say on Corbus Pharmaceuticals recently announced quarterly report
Check out if Corbus Pharmaceuticals is spiking on competitors!
Corbus Pharmaceuticals, which may be a good buyer, showed buying intent in Masked Content Topic
Check if Corbus Pharmaceuticals has recently received funding, and reach out quickly before it becomes old news!
Product Launch: Get notified when Corbus Pharmaceuticals launches new products
Click to see if Corbus Pharmaceuticals had a recent Job posting/layoffs
Website visits: Recent activity has been detected on your website
Congratulate Masked Content for being promoted to Masked Content at Corbus Pharmaceuticals
Recommended Actions
Reach out to Masked Content who joined Corbus Pharmaceuticals as Masked Content
Find 3 more new buyers
Compare Similar Companies to Corbus Pharmaceuticals
Compare insights from companies similar to Corbus Pharmaceuticals, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
$7.8M
11-50
Private
$40M
1996
CB
Chaim BrickmanSenior Medical Director, Clinical Development & Pharmacovigilance
Company Profile Activity
Activity Insights
Corbus Pharmaceuticals is experiencing very low activity levels compared to other companies in the Business Services sector.
What does this means?
Corbus Pharmaceuticals is drawing exceptional interest within the Business Services industry, suggesting notable developments or strong market momentum, learn more about Corbus Pharmaceuticals.
Corbus Pharmaceuticals financials insights
Gather financial insights about Corbus Pharmaceuticals, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2020
Debt
$50M
2024
Share Placement
$16.8M
Corbus Pharmaceuticals Tech Stack
Most Recent Scoops
Partnership
Project
Laboratory Operations, Medical Research, Clinical Operations
Person-Based
Stake & Stock Ownership, Finance
Open Position
Person-Based
Medical Research, Pharmaceuticals, Clinical Operations
Person-Based
Medical Research, Clinical Operations
Corbus Pharmaceuticals News & Media
Corbus Pharmaceuticals Holdings, Inc. (CRBP) Phase 1b Topline Results for CRB-913 in Obesity and Potential as Weight Loss Therapy Transcript
Corbus Pharmaceuticals Holdings, Inc. (CRBP) Phase 1b Topline Results for CRB-913 in Obesity and Potential as Weight Loss Therapy September 14, 2026 8:00 AM...Corbus Pharmaceuticals Announces Positive Topline Data from CANYON-1 Study of Daily Oral CRB-913 for the Treatment of Obesity
NORWOOD, Mass., Sept. 14, 2026 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP), a clinical-stage company focused on new therapies in oncology and obesity, today announced positive topline data from the Company’s CANYON-1 Phase 1b clinical trial of CRB-913 for the treatment of obesity. The data demonstrated statistically significant and clinically meaningful weight loss at all three doses with the 60 mg dose achieving a mean weight loss of 5% at 12 weeks. CRB-913Corbus Pharmaceuticals to Host Conference Call to Discuss Topline Data from CANYON-1 Clinical Trial and the Potential of CRB-913 In Obesity
Virtual Webcast to be Held Monday, September 14, 2026, at 8:00 AM EDT Virtual Webcast to be Held Monday, September 14, 2026, at 8:00 AM EDTCorbus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
NORWOOD, Mass., Aug. 17, 2026 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP), a clinical-stage company focused on new therapies in oncology and obesity, today announced the grant of inducement equity awards outside of the Company's stockholder-approved equity compensation plans to Leonardo Nicacio in connection with his commencement of employment as Chief Medical Officer of the Company. The grants were approved by the Compensation Committee of the Board of Directors eff
Read more news
Top Business Services Companies
See more top companies
Frequently Asked Questions Regarding Corbus Pharmaceuticals
Sign Up For FreeTo access detailed company insights
Corbus Pharmaceuticals Holdings, Inc., a biopharmaceutical company, develops products to defeat serious illness. It develops CRB-701, an antibody drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload of monomethyl auristatin E (MMAE), which is in Phase I clinical trial; CRB-601, an anti-integrin... Read More
